Roche CDR (CAD Hedged) (ROG) Fair Value & Analysis
Healthcare · CA · Market cap C$466B (≈ $337B)
What is Roche CDR (CAD Hedged) really worth?
A solid business, currently priced close to our fair value of C$26.43.
As of Aug 19, 2026, the fair value of Roche CDR (CAD Hedged) is C$26.43 per share against a price of C$28.81, so the fair value sits 8% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 19, 2026
From 22 valuation models · updated 17 days ago
Share price +8.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (C$17.69 to C$43.86) leaves room in how you read the outcome.
Price vs Fair Value (18 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
18‑month range C$18.06 – C$28.81 · fair‑value band C$17.69 – C$43.86 · the C$28.81 price screens above the C$26.43 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Roche CDR (CAD Hedged) (ROG) currently trades at C$28.81, while our model-based Fair Value estimate is C$26.43, implying the stock looks roughly 9.0% fairly valued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of C$15.80 per share, and 0 of the 22 models we run sit above the C$28.81 price. Bear case: the Earnings-Based group reads lowest at C$9.19, and 22 of the 22 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Roche CDR (CAD Hedged) generated revenue of C$63.5B at a net margin of 14.9%. Revenue grew 3.6% year over year. It earns a return on equity of 31.3%. Net debt stands at C$26.1B. Fundamentals as of Aug 19, 2026
Our scenario range runs from C$17.69 (bear case) to C$43.86 (bull case); at C$28.81, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 52% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at −8%, ROG screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 22 models by family
Widest divergence: Multiples (C$15.80) versus Asset-Based (C$1.63). Highest evidence: FCF DCF (76).
Notify me when ROG reaches fair value
Put ROG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 71 · Market factors (momentum, volatility) 77
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Full company description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Roche CDR (CAD Hedged) reported revenue of CHF 63.4B in FY2025 versus CHF 65.8B in FY2022, a compound −1.3%/yr. Reported net income was CHF 12.9B in FY2025, compounding +1.2%/yr from FY2022.
Watch ROG: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,176 | $389.47 | −67% |
| Johnson & Johnson, JNJ | $275.23 | $169.04 | −39% |
| AbbVie Inc ABBV | $256.46 | $67.72 | −74% |
| Roche Holding RO | CHF 374.60 | CHF 306.54 | −18% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 123.74 | CHF 114.90 | −7% |
| Novo Nordisk A/S NOVOB | kr 295.50 | kr 409.46 | +39% |
| Amgen Inc AMGN | $437.23 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $151.00 | $146.50 | −3% |
| Pfizer Inc PFE | $28.02 | $24.87 | −11% |
Compare Roche CDR (CAD Hedged) with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Roche CDR (CAD Hedged) (ROG) overvalued or undervalued?
What is the fair value of ROG?
What is the quality score of ROG?
What is the price target for Roche CDR (CAD Hedged) (ROG)?
What is the Roche CDR (CAD Hedged) stock forecast for 2026?
What is the revenue of Roche CDR (CAD Hedged) (ROG)?
What is the net profit margin of ROG?
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.